Recommendation 1.1
➤ All women diagnosed with epithelial ovarian cancer should be offered
germline genetic testing for BRCA1, BRCA2 and other ovarian cancer
susceptibility genes, irrespective of their clinical features or family
cancer history. Somatic tumor testing for BRCA1 and BRCA2 pathogenic
or likely pathogenic variants should be performed in women who do not
carry a germline pathogenic or likely pathogenic BRCA1/2 variant. (Strong
recommendation; EB-B-I)
Recommendation 1.2
➤ Women diagnosed with clear cell, endometrioid or mucinous ovarian cancer
should be offered somatic tumor testing for mismatch repair deficiency
(dMMR). (Moderate recommendation; EB-B-I)
Recommendation 1.3
➤ Testing for dMMR may be offered to women diagnosed with other
histological types of epithelial ovarian cancer. (Moderate recommendation;
EB-B-I)
Recommendation 1.4
➤ Those genetic evaluations should be conducted in conjunction with health
care providers, including genetic counselors, familiar with the diagnosis
and management of hereditary cancer syndromes, to determine the most
appropriate testing strategy and discuss implications of the findings,
positive or negative, for first- or second-degree blood relatives. (Moderate
recommendation; IC-L)
Recommendation 1.5
➤ First- or second-degree blood relatives of an ovarian cancer patient with a
known germline pathogenic cancer susceptibility gene mutation or variant
should be offered individualized genetic risk evaluation, counselling and
genetic testing. (Strong recommendation; EB-B-H)
Recommendation 2.1
➤ Women diagnosed with epithelial ovarian cancer with identified germline
or somatic pathogenic or likely pathogenic variants in BRCA1 and BRCA2
genes should be offered treatments that are FDA-approved under their
labeled indication in the upfront and the recurrent setting. BRCA1/2
pathogenic or likely pathogenic variants qualify for and have been
associated with higher rates of response to FDA-approved treatments such
as PARP inhibitors. (Strong recommendation; EB-B-H)
Diagnosis
